Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
Pfizer Inc. has announced that it will lay off 100 employees from its former Seagen headquarters as part of ongoing cost-cutting measures. This decision reflects the company's efforts to streamline operations and reduce expenses in a challenging economic environment. The layoffs are a response to the need for financial adjustments within the organization. Pfizer's restructuring plan aims to enhance efficiency and maintain competitiveness in the pharmaceutical industry.
Pfizer Inc. has announced layoffs affecting approximately 200 employees in its biotech division due to a loss of interest in commercializing a PROTAC inhibitor. This decision comes as the company shifts its focus away from this specific project, which has led to a restructuring within the organization. The layoffs are expected to impact operations significantly, as the affected employees were integral to the development of this therapeutic approach. The company is navigating a challenging landscape in biotech, prompting these workforce reductions to realign its strategic priorities.
Pfizer Inc. has announced that it will lay off 62 employees at its Tampa facility. This decision is part of a broader restructuring effort within the company. The layoffs are set to take effect on October 1, 2023. Pfizer has not specified the departments affected by these cuts, but the move reflects ongoing adjustments in response to market conditions. The company continues to evaluate its workforce needs as it navigates changes in the pharmaceutical landscape.
Pfizer Inc. has laid off 100 workers at its former Seagen headquarters located in the Seattle area. This decision reflects ongoing adjustments within the company as it navigates changes in its operational strategy. The layoffs are part of a broader trend in the pharmaceutical industry, but specific reasons for these job cuts at Pfizer were not detailed in the report. The affected employees were notified of their termination on October 1, 2023. Pfizer's restructuring efforts highlight the challenges faced by companies in the current market environment.
Pfizer Inc. has announced the layoff of 56 employees as part of a restructuring of its research and development operations in San Diego. This decision follows the company's recent sale of a site for $255 million, indicating a significant shift in its operational footprint in the area. The layoffs are part of a broader strategy to optimize resources and focus on key areas of research. Pfizer's adjustments reflect ongoing changes in the pharmaceutical industry and the company's efforts to streamline its operations. The layoffs are effective immediately as the company moves forward with its plans.
Pfizer Inc. has announced plans to cut around 100 jobs at its Ringaskiddy plant in Ireland. This decision is part of a broader restructuring effort within the company. The layoffs are expected to impact various roles at the facility, although specific departments affected were not disclosed. Pfizer's move reflects ongoing adjustments in its operational strategy, aiming to enhance efficiency and adapt to changing market conditions. The company has not provided a specific timeline for when these layoffs will take effect.
Pfizer Inc. is implementing a cost-cutting strategy that includes planned layoffs in its manufacturing operations in Ireland. The company has not specified the exact number of positions that will be affected by these upcoming layoffs. This move is part of a broader effort to streamline operations and reduce expenses amid changing market conditions. Pfizer's decision reflects ongoing challenges in the pharmaceutical industry and aims to enhance operational efficiency. Further details regarding the timeline for these layoffs have yet to be disclosed.
No one has shared a story from Pfizer, Inc. yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.